Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer

• Main Authors: Farhad Shahi (Author), Mojtaba Gorji, Assistant Professor of Pediatric Oncology (Author), Mehrdad Payandeh, Assistant Professor of Hematology & Oncology (Author), Hamid Rezvani, Associate Professor of Hematology & Oncology (Author), Mohammad Vaezi, Associate Professor of Hematology & Oncology (Author), Sharareh Seifi, Assistant Professor of Hematology & Oncology (Author), Alireza Baari, Post doctoral fellowship (Author), Reza Khalili-Dizaji, Post doctoral fellowship (Author), Seyed Mehdi Hashemi, Associate Professor of Hematology & Oncology (Author), Saeid Salimi, post doctoral fellowship (Author), Hosein Kamranzadeh, Associate Professor of Hematology & Oncology (Author), Babak Shazad, Post doctoral fellowship (Author), Sina Salari, Associate Professor of Hematology & Oncology (Author), Davoud Oulad Dameshghi, Assistant Professor of Hematology & Oncology (Author), Mehdi Sarkheil, Post doctoral fellowship (Author), Mehrzad Mirzania, Associate Professor of Hematology & Oncology (Author), Nassim Anjidani, Pharm. D. (Author)
• Format: Book
• Published: Elsevier, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACT: Background: CRC is the second and third most common cancer in women and men, respectively. The national comprehensive cancer network guidelines recommend oxaliplatin-based chemotherapy as a preferred regimen for patients with advanced or metastatic colon cancer. Oxaliplatin is also used in...